Financial Performance - The net loss for the nine months ended September 30, 2025, was $6,503,698, compared to a net loss of $4,025,361 for the same period in 2024, indicating an increase in losses of about 61.6%[11] - For the nine months ended September 30, 2025, eXoZymes reported a net loss of $6,503,698, compared to a net loss of $4,025,361 for the same period in 2024, reflecting an increase in losses of approximately 62%[80] - The company has substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status[22] - The company reported no operating income for the three and nine months ended September 30, 2025, maintaining a consistent trend from the previous year[11] - The company incurred net cash used in operating activities of $(4,528,240) for the nine months ended September 30, 2025, compared to $(2,798,123) in 2024, an increase of approximately 62%[16] Assets and Equity - Total assets decreased from $13,034,404 on December 31, 2024, to $7,719,049 on September 30, 2025, representing a decline of approximately 40.5%[9] - Total stockholders' equity fell from $10,420,775 on December 31, 2024, to $5,374,422 on September 30, 2025, a decrease of approximately 48.5%[9] - Cash and cash equivalents decreased from $9,719,310 at the beginning of the period to $5,098,687 at the end of the period, a reduction of about 47%[16] - The fair value of cash and cash equivalents as of September 30, 2025, is $5,098,687, with no Level 2 or Level 3 measurements reported[42] Research and Development - Research and development costs for the nine months ended September 30, 2025, were $2,594,765, up from $1,238,463 in 2024, reflecting a significant increase of approximately 109%[11] - For the nine months ended September 30, 2025, research and development costs prior to grant offsets amounted to $3,748,110, compared to $3,046,169 for the same period in 2024, reflecting an increase of approximately 22.9%[51] - Research and development costs, net of grants, were $2,594,765 for the nine months ended September 30, 2025, compared to $1,238,463 in 2024, reflecting a significant increase of approximately 110%[1] Grants and Funding - The Department of Energy contributed 89% and the NIH contributed 11% of all grant reimbursements for the nine months ended September 30, 2025[31] - Grant reimbursements for the nine months ended September 30, 2025, totaled $1,120,907, down from $1,756,852 in 2024, indicating a decrease of about 36.3%[50] - The balance of grants receivable at the end of the nine months ended September 30, 2025, was $302,643, a decrease from $553,963 at the end of the same period in 2024, representing a decline of approximately 45.2%[48] - eXoZymes received a $3 million share of a $9.2 million grant from the U.S. National Science Foundation aimed at enhancing cell-free systems, awarded on July 1, 2025[49] Stock and Compensation - The weighted average number of common shares outstanding increased from 6,251,158 in 2024 to 8,377,513 in 2025, reflecting a growth of about 34%[11] - eXoZymes' stock-based compensation for the nine months ended September 30, 2025, was $1,066,461, compared to $808,362 for the same period in 2024[71] - The total number of stock options outstanding was 1,982,830 shares as of September 30, 2025, with a weighted average exercise price of $5.51[72] - The company has unrecognized stock-based compensation of $3,073,349 as of September 30, 2025[71] - The company issued 19,440 shares of common stock to key executives on May 12, 2025, valued at $243,778, in lieu of cash bonuses[61] Operating Costs - Total operating costs for the nine months ended September 30, 2025, were $7,020,981, up from $3,948,789 in 2024, indicating an increase of approximately 78%[1] - General and administrative costs for the nine months ended September 30, 2025, totaled $4,426,216, compared to $2,710,326 in 2024, marking an increase of approximately 63.3%[11] - The company recognized operating lease expenses of $280,898 for both the nine months ended September 30, 2025, and 2024, indicating no change year-over-year[103] Lease and Liabilities - The total lease liabilities as of September 30, 2025, amounted to $1,200,888 for operating leases and $119,236 for finance leases[104] - The company entered into a lease for new office space with an initial base rent of $13,277 per month, which will increase annually, and the lease term is set for 60 months[94] - eXoZymes has recorded right-of-use assets of $1,124,925 and operating lease liabilities of $1,200,888 as of September 30, 2025, with a weighted average remaining lease term of 3.83 years[102] Miscellaneous - The company established a wholly owned subsidiary, NCTx LLC, on May 5, 2025, focused on developing N-trans-caffeoyltyramine, a rare plant-derived compound[21] - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[29] - The company has not generated revenue to date and is in a pre-revenue status, raising concerns about its ability to continue as a going concern without additional funding[22] - The company did not experience any credit risk losses during the three and nine months ended September 30, 2025, and 2024[38]

Financial Performance - The net loss for the six months ended June 30, 2025, was $4.22 million, compared to a net loss of $2.37 million for the same period in 2024, indicating an increase in losses of approximately 77.9%[10] - Total operating costs for the six months ended June 30, 2025, were $4.50 million, up from $2.34 million in 2024, reflecting an increase of approximately 92.7%[10] - The company reported no operating income for the three and six months ended June 30, 2025, consistent with the previous year[10] - The Company incurred net losses of $4,216,707 and $2,368,988 for the six months ended June 30, 2025 and 2024, respectively, indicating a year-over-year increase in losses of approximately 77%[21] - For the six months ended June 30, 2025, the net loss was $4,216,708, compared to a net loss of $2,368,988 for the same period in 2024, resulting in a basic and diluted loss per share of $(0.50) compared to $(0.38) in 2024[73] Assets and Equity - As of June 30, 2025, total assets decreased to $9.68 million from $13.03 million as of December 31, 2024, representing a decline of approximately 25.5%[8] - Stockholders' equity decreased to $7.24 million as of June 30, 2025, from $10.42 million at the end of 2024, a decline of approximately 30.5%[8] - Cash and cash equivalents decreased to $6.99 million as of June 30, 2025, from $9.72 million at the end of 2024, a reduction of about 28.1%[15] - Cash and cash equivalents held by the Company as of June 30, 2025, amounted to $6,985,858, with approximately $6,735,858 exceeding FDIC insured limits[35][37] Research and Development - Research and development costs for the six months ended June 30, 2025, were $1.38 million, compared to $514,977 in 2024, marking an increase of approximately 168.5%[10] - For the six months ended June 30, 2025, research and development costs amounted to $2,268,677, an increase of 23.8% from $1,832,855 in the same period of 2024[49] - The Department of Energy contributed 98% and the NIH contributed 2% of all grant reimbursements for the six months ended June 30, 2025, highlighting a concentration of funding sources[30] - The Company established a wholly owned subsidiary, NCTx LLC, focused on developing N-trans-caffeoyltyramine, a rare plant-derived compound[20] Grants and Funding - Grants received for the six months ended June 30, 2025, totaled $864,433, down 32.0% from $1,272,127 in 2024[47] - The balance of grants receivable at the end of the period decreased significantly to $257,407 in 2025 from $1,147,171 in 2024, representing a decline of 77.5%[46] - The Company recognizes grant reimbursements from the Federal government as offsets against research and development expenses, with no allowance for credit losses recorded[44][45] Stock and Compensation - The weighted average number of common shares outstanding for the six months ended June 30, 2025, was 8,372,564, compared to 6,250,557 in 2024, an increase of approximately 33.9%[10] - The company incurred stock-based compensation expenses of $884,531 for the six months ended June 30, 2025, compared to $491,085 in 2024, an increase of approximately 80%[15] - Stock-based compensation for the six months ended June 30, 2025, was $640,753, up 30.4% from $491,085 in 2024[65] - The company has unrecognized stock-based compensation of $3,194,925 as of June 30, 2025[65] Operational Highlights - The company had no revenue reported for the three and six months ended June 30, 2025, indicating a continued focus on development rather than sales[10] - The company operates as a single reportable operating segment focused on the research and commercialization of exozyme biosolutions[54] - The company has not generated revenue from operations, remaining in a pre-revenue status[21] Lease and Liabilities - As of June 30, 2025, the company had total operating lease liabilities of $1,264,863 and finance lease liabilities of $129,593[95] - The company recognized operating lease expenses of $187,265 for both the six months ended June 30, 2025, and 2024[96] - The company executed a lease for new office space with an initial base rent of $13,277 per month, which will increase annually[87] Future Outlook - The Company has sufficient working capital for the near term but faces substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls[21] - The company plans to issue stock options to purchase 235,817 shares at an exercise price of $12.69 per share, which will vest over four years[98] - On July 1, 2025, the company was awarded a $3 million share of a $9.2 million grant from the U.S. National Science Foundation aimed at enhancing cell-free systems[99]

Financial Performance - The company reported a net loss of $1,856,421 for the three months ended March 31, 2025, compared to a net loss of $1,008,458 for the same period in 2024, indicating an increase in losses of approximately 84.2%[11] - Basic and diluted loss per share for the three months ended March 31, 2025, was $(0.22), compared to $(0.16) for the same period in 2024[61] - The net loss for the three months ended March 31, 2025, was $1,856,421, compared to a net loss of $1,008,458 for the same period in 2024[11] - The company experienced a net cash decrease of $(1,207,833) during the three months ended March 31, 2025, compared to an increase of $47,263 in the same period of 2024[21] Assets and Liabilities - Total assets decreased from $13,034,404 on December 31, 2024, to $11,525,692 on March 31, 2025, representing a decline of approximately 11.5%[9] - Cash and cash equivalents decreased from $9,719,310 at the beginning of the period to $8,511,477 at the end of the period, a reduction of approximately 12.4%[16] - The Company had cash equivalents of $8,159,472 as of March 31, 2025, with approximately $8,186,086 in cash exceeding FDIC insurance limits[31][32] - The Company reported right-of-use assets of $1,263,855 and operating lease liabilities of $1,326,424[79] - The total future payments due under operating leases as of March 31, 2025, amount to $1,560,636, with the largest payment of $378,576 due in 2028[81] Operating Costs - Total operating costs increased to $1,950,728 in Q1 2025 from $1,008,458 in Q1 2024, reflecting a rise of approximately 93.3%[11] - Cash used in operating activities was $(1,133,533) for the three months ended March 31, 2025, compared to cash provided of $281,199 in the same period of 2024, indicating a significant decline in operational cash flow[21] - Stock-based compensation for the three months ended March 31, 2025, was $317,277, compared to $142,810 for the same period in 2024[53] Research and Development - Research and development costs net of grants amounted to $575,016 for Q1 2025, up from $277,582 in Q1 2024, marking an increase of approximately 107.2%[11] - Research and development costs for the three months ended March 31, 2025, amounted to $1,150,797, compared to $986,282 for the same period in 2024, reflecting an increase of approximately 16.6%[40] - The Company received grant reimbursements of $571,822 and $674,158 for research and development costs for the three months ended March 31, 2025, and 2024, respectively[39] Shareholder Information - The weighted average number of common shares outstanding increased from 6,250,002 in Q1 2024 to 8,367,810 in Q1 2025, reflecting a growth of approximately 33.9%[11] - The Company has a total of 1,747,789 stock options outstanding as of March 31, 2025, with a weighted average remaining contractual life of 5.54 years[54] - As of March 31, 2025, stock options to purchase 632,757 shares of Common Stock were vested, with a weighted average exercise price of $4.57[53] Legal and Compliance - The company has not recorded any accrued royalties under the exclusive license agreement as of March 31, 2025[68] - The company has met all development milestones required under the license agreement as of March 31, 2025[69] - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from various reporting requirements[24] Subsidiaries and Ventures - The company established a wholly owned subsidiary, NCTx LLC, focused on developing a rare plant-derived compound relevant to metabolic health[82] - The company has filed a provisional patent application for deuterated cannabinoid molecules in a joint venture with Neuractas Therapeutics, although no business activities have occurred to date[19] Funding and Grants - The Company has a minority interest of 48% held by MDB Capital Holdings, LLC as of March 31, 2025, following the dilution from the November 2024 IPO[18] - The Company reported a significant concentration of risk, with 97% of grant reimbursements coming from the Department of Energy and 3% from the NIH for the three months ended March 31, 2025[26] - The balance of grants receivable at the end of the period was $595,160 as of March 31, 2025, down from $1,111,611 at the end of March 2024, indicating a decrease of approximately 46.5%[39]

Funding and Financial Position - eXoZymes Inc. has received a total of $13,639,011 in grants from various sources, including $50,000 from the Gates Foundation for terpene synthesis and funding from the Department of Energy for isobutanol production[36][37]. - The company recognizes the challenges in obtaining new grants and may need to raise additional capital if current funding sources are exhausted[37]. - eXoZymes incurred net losses of $5,861,335 and $2,038,389 for the years ended December 31, 2024 and 2023, respectively, and used cash for operations of $(8,505,650) and $(1,180,870) during the same periods[95]. - eXoZymes is a pre-revenue, development-stage company and does not expect to generate revenue or net income until it successfully commercializes its first products[96]. - The company anticipates requiring additional capital to support its long-term business plan, which may involve private and public offerings, borrowings, and potential mergers[97]. - The company raised a gross amount of $15,901,328 from its initial public offering (IPO) on November 11, 2024, with a net proceeds of $15,206,543[178]. - Approximately $5,149,980 of the net proceeds has been utilized, including $4,243,022 for related party loans, $143,615 for lab equipment, and $763,343 for working capital[179]. - The company has not paid any cash dividends in the past and has no immediate plans to do so, intending to reinvest earnings into technology and operations[163]. - The company has received a $1,000,000 grant from the Department of Defense for biomanufacturing initiatives, which will enhance its working capital position[196]. - The company plans to utilize proceeds from the IPO for staffing, R&D, and repayment of approximately $4,243,022 in loans[194]. Business Strategy and Market Focus - The company plans to focus on low-volume, high-value chemical compounds, particularly those that can serve as active ingredients in nutraceuticals and have potential as active pharmaceutical ingredients (APIs)[38][39]. - eXoZymes aims to leverage its unique technology platform to create commercial value and has demonstrated capabilities in developing exozyme biosolutions for nutraceuticals and pharmaceuticals[29][30]. - The company anticipates that partnerships will be essential for expanding its product offerings and accessing new markets, as it currently lacks the resources to pursue all potential markets independently[42][43]. - eXoZymes' focus on nutraceuticals is seen as a risk-minimizing strategy that can also serve as a foundation for future pharmaceutical developments[39]. - eXoZymes plans to focus on nutraceuticals with pharmaceutical potential, leveraging existing knowledge and infrastructure for multiple biosolutions[54]. - The company is developing exozyme-based biosolutions for the nutraceutical, pharmaceutical, and biofuels industries, which will require addressing various regulatory compliance[70]. Technology and Innovation - eXoZymes' technology allows for the production of valuable chemicals using AI-designed exozymes, which can scale linearly and avoid the challenges associated with traditional cell-based synthetic biology[27][31]. - The company has a decade of expertise in enzyme engineering and has integrated AI and biochemical pathway engineering to enhance its biosolutions[32]. - eXoZymes' biomanufacturing platform utilizes cell-free exozymes, enhancing control and efficiency in producing small molecule natural products[48]. - The technology aims to overcome scalability challenges in synthetic biology, achieving higher titers, yields, and product purity compared to traditional methods[50]. - eXoZymes's unique technological approach allows for the production of diverse chemicals through multi-step cell-free biocatalysis, providing a competitive advantage[81][86]. - The platform allows for complex multi-step chemical conversions in a single bioreactor, improving productivity and reducing costs[53]. - The company believes its unique technological approach and intellectual property on recycling essential cofactors provide a competitive advantage over traditional synthetic biochemical companies[121]. Regulatory and Competitive Landscape - eXoZymes faces competition from established companies in the synthetic biology space, including Codexis, Inc. and Solugen Inc., which focus on enzyme engineering and biofuels[83]. - The company anticipates that regulations regarding cannabinoids and biofuels will continue to evolve, impacting its product development and market strategies[75][80]. - The company may face unique regulatory hurdles due to the novel nature of its bio-synthesized compounds, which could delay development and commercialization[104]. - Future collaboration arrangements may pose risks, including collaborators not performing as expected or failing to comply with regulatory requirements[116]. - The company faces risks related to intellectual property infringement claims, which could delay commercialization of its products[132]. Operational and Management Considerations - The company employs approximately 31 full-time employees, with 18 focused on R&D efforts and plans to expand personnel and manufacturing capabilities[89]. - eXoZymes's ability to retain its current management and scientific team is critical for its success, as losing key personnel could significantly impact operations[106]. - The company currently lacks significant sales, marketing, manufacturing, and distribution capabilities, which are essential for product commercialization[114]. - Collaborations with third parties for research, testing, manufacturing, and distribution are critical for the company's business success[115]. - The company relies on a single facility for operations, posing a significant risk to business continuity in case of disruptions[146]. Financial Performance and Projections - Total operating income for 2024 was $0, a decrease of 100% from $70,069 in 2023[186]. - Research and development costs increased by $1,341,286 to $1,868,766 in 2024, reflecting a 254.3% increase due to higher salaries and lab expenses[187]. - Total general and administrative costs rose to $4,063,339 in 2024, a 203.5% increase from $1,338,811 in 2023[186]. - Net operating loss for 2024 was $5,932,105, compared to a loss of $1,796,222 in 2023, marking a 230.3% increase[186]. - Cash and cash equivalents surged to $9,719,310 in 2024, a 14,508.3% increase from $66,533 in 2023[189]. - Total assets increased by 266.3% to $13,034,404 in 2024, up from $3,558,509 in 2023[189]. - Working capital improved to $9,487,137 in 2024, compared to a negative working capital of $(1,201,680) in 2023, reflecting an increase of $10,688,817[193]. Market Risks and Economic Factors - The company is aware of potential recessionary indicators in the U.S. economy, which could impact the business environment and capital markets[214]. - The company does not anticipate significant impacts from inflation on its operations to date[211]. - Supply chain issues are being monitored, but the company does not expect them to significantly affect business activities[213]. - The company is focused on developing new technologies, but there is uncertainty regarding their commercial viability and market acceptance[216]. - No current trends, events, or uncertainties are identified that would materially affect the company's financial condition in the near term[217].

Financial Performance - Net loss for the nine months ended September 30, 2024, was $4,025,361, compared to a net loss of $939,825 for the same period in 2023, reflecting a year-over-year increase of 328.5%[10] - The company reported a net cash used in operating activities of $(2,798,123) for the nine months ended September 30, 2024, compared to $(397,590) for the same period in 2023, indicating a significant increase in cash outflow[14] - The net loss for the three months ended September 30, 2024, was $(1,656,373), representing a 218.2% increase compared to the same period in 2023[92] - The accumulated deficit increased to $(10,109,984) as of September 30, 2024, from $(6,084,623) on December 31, 2023, representing a deterioration of 66.5%[8] - For the nine months ended September 30, 2024, the net loss was $4,025,361, compared to a net loss of $939,825 for the same period in 2023, resulting in a basic and diluted loss per share of $(0.64) compared to $(0.15) in 2023[60] Revenue and Funding - The company raised gross proceeds of $15,000,000 from its IPO by selling 1,875,000 shares of Common Stock, with net proceeds of approximately $14,321,686 after underwriting costs[18] - The company plans to use the IPO proceeds for expanding production capabilities, staffing, R&D, and repaying approximately $4,392,455 in intercompany loans[18] - The company has received grants from the Department of Energy (64%) and NIH (36%) for the nine months ended September 30, 2024, indicating a reliance on government funding[26] - The Company received a cost share grant of approximately $1,000,000 from the Department of Defense BioMADE initiative for cell-free biomanufacturing of isobutanol[85] - Grants received for the nine months ended September 30, 2024, totaled $1,756,852, compared to $2,180,581 for the same period in 2023, reflecting a decrease of approximately 19.4%[38] Operating Costs - Operating costs for the three months ended September 30, 2024, totaled $1,611,726, significantly higher than $391,846 for the same period in 2023, indicating a rise of 311.5%[10] - Total general and administrative costs for the three months ended September 30, 2024, rose by 144.1% to $888,239[92] - For the nine months ended September 30, 2024, total operating costs rose by 347.7% to $3,948,789, with significant increases in general and administrative costs[93] - Compensation costs for the three months ended September 30, 2024, surged by 358.3% to $546,095 compared to the same period in 2023[92] - Research and development costs for the three months ended September 30, 2024, amounted to $723,487, reflecting a 2,489.8% increase from the previous year[92] Assets and Liabilities - Total current assets increased to $1,422,591 as of September 30, 2024, up from $1,213,614 on December 31, 2023, representing a growth of 17.2%[8] - Total liabilities rose significantly to $7,161,683 as of September 30, 2024, compared to $3,942,828 on December 31, 2023, marking an increase of 81.4%[8] - Cash and cash equivalents increased to $233,935 as of September 30, 2024, from $66,533 at the beginning of the period, showing a growth of 251.5%[14] - Working capital decreased to $(4,379,709) as of September 30, 2024, down from $(1,201,680) at the end of 2023, primarily due to reduced grant reimbursements[101] - Total current liabilities surged by 140.2% to $5,802,300 compared to $2,415,294 at the end of 2023[96] Research and Development - Research and development costs for the nine months ended September 30, 2024, were $1,238,463, compared to $67,095 for the same period in 2023, an increase of 1745.5%[10] - For the nine months ended September 30, 2024, research and development costs before grant offsets totaled $3,046,169, an increase of 30.7% compared to $2,332,503 in 2023[39] - The increase in research and development costs was attributed to higher salaries and lab expenses[95] Stock and Equity - The weighted average of common shares outstanding was 6,251,158 for the nine months ended September 30, 2024, compared to 6,250,002 for the same period in 2023, reflecting a slight increase[10] - The total number of stock options outstanding was 1,752,983, with a weighted average exercise price of $4.57[54] - Stock-based compensation for the nine months ended September 30, 2024, was $808,362, compared to $174,440 in 2023, indicating a significant increase of 363.5%[53] - The unrecognized stock-based compensation as of September 30, 2024, was $4,871,597, indicating potential future expenses related to stock options[53] - The Company executed a simple agreement for future equity (SAFE) with MDB Capital Holdings LLC for $785,000 and with Paul Opgenorth for $15,000, totaling $800,000 funded as of September 30, 2024[81] Legal and Compliance - The company has no pending or threatened legal claims as of September 30, 2024, which may positively impact its operational stability[61] - The company has met all development milestones under its License Agreement with The Regents of the University of California as of September 30, 2024[69] - Payments made to The Regents in connection with the License Agreement totaled $337,847 from 2019 to September 30, 2024[71] Future Outlook - As of September 30, 2024, the company had working capital of approximately $9,941,977, which is expected to be sufficient to pursue operational objectives[19] - The company does not currently expect significant impacts from supply chain issues or inflation on its business activities[63] - Future payments due under operating leases as of September 30, 2024, total $1,733,274, with a weighted average discount rate of 7.88%[80]

As filed with the Commission on October 21, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 8 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2836 47-228900 (I.R.S. Employer Identification No.) 750 Royal Oaks Dri ...

As filed with the Commission on October 4, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM S-1 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2836 47-228900 (I.R.S. Employer Identification No.) 750 Royal Oaks Drive, Suite 106 Monrovia, CA 91016 (626) 415-1488 (Address, ...

As filed with the Commission on September 19, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2836 47-228900 (I.R.S. Employer Identification No.) 750 Royal Oaks D ...

As filed with the Commission on September 6, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2836 47-228900 (I.R.S. Employer Identification No.) 750 Royal Oaks Dr ...

As filed with the Commission on August 1, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Andrew Hudders, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP 711 Third Avenue, 17th Floor New York, NY 10017 (212) 907-7300 ahudders@g ...